 | Up a level |
Papapoulos, S; Lippuner, Kurt; Roux, C; Lin, C J F; Kendler, D L; Lewiecki, E M; Brandi, M L; Czerwiński, E; Franek, E; Lakatos, P; Mautalen, C; Minisola, S; Reginster, J Y; Jensen, S; Daizadeh, N S; Wang, A; Gavin, M; Libanati, C; Wagman, R B and Bone, H G (2015). The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporosis international, 26(12), pp. 2773-2783. Springer 10.1007/s00198-015-3234-7
Ralston, SH; Binkley, N; Boonen, S; Kiel, DP; Reginster, JY; Roux, C; Chen, L; Rosenberg, E; Santora, A; FOCUS-D, (FOSAVANCE vs.Standard Care-Use; Study, of Vitamin D) Trial (2011). Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency. Calcified tissue international, 88(6), pp. 485-494. New York, N.Y.: Springer 10.1007/s00223-011-9482-4
Reid, DM; Devogelaer, JP; Saag, K; Roux, C; Lau, CS; Reginster, JY; Papanastasiou, P; Ferreira, A; Hartl, F; Fashola, T; Mesenbrink, P; Sambrook, PN; Perrelet, Romain; HORIZON, investigators (2009). Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet, 373(9671), pp. 1253-1263. London: Elsevier 10.1016/S0140-6736(09)60250-6
